TrialThe Lancet. Respiratory medicine2022

Safety and immunogenicity of a live-attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine in adults: randomised, double-blind, placebo-controlled, phase 1 and 2 trials.

Fengcai Zhu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.